Rossmore Private Capital Buys 2,122 Shares of Stryker Corporation $SYK

Rossmore Private Capital grew its holdings in Stryker Corporation (NYSE:SYK) by 12.2% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 19,561 shares of the medical technology company’s stock after acquiring an additional 2,122 shares during the period. Rossmore Private Capital’s holdings in Stryker were worth $6,892,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of SYK. Brighton Jones LLC lifted its holdings in Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after buying an additional 609 shares during the period. Schnieders Capital Management LLC. purchased a new stake in Stryker in the 2nd quarter worth approximately $205,000. Marshall Wace LLP lifted its holdings in Stryker by 107.9% in the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after buying an additional 77,831 shares during the period. Nebula Research & Development LLC purchased a new stake in Stryker in the 2nd quarter worth approximately $219,000. Finally, HUB Investment Partners LLC purchased a new stake in Stryker in the 2nd quarter worth approximately $253,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on SYK. William Blair reiterated an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. BTIG Research dropped their price objective on Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a report on Friday, May 1st. JPMorgan Chase & Co. lowered their target price on Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Wells Fargo & Company dropped their price target on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Finally, Leerink Partners began coverage on Stryker in a report on Monday, April 13th. They issued an “outperform” rating and a $410.00 price objective for the company. Sixteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $395.48.

Insider Transactions at Stryker

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of Stryker stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares in the company, valued at approximately $3,728,937.45. The trade was a 28.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.60% of the company’s stock.

Stryker Price Performance

SYK opened at $306.74 on Monday. The stock has a fifty day simple moving average of $329.68 and a two-hundred day simple moving average of $351.50. The company has a market cap of $117.59 billion, a price-to-earnings ratio of 35.50, a price-to-earnings-growth ratio of 1.93 and a beta of 0.80. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Research analysts predict that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s payout ratio is presently 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.